1 / 9

Background and Objective

Background and Objective. In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S) was associated with a significantly increased risk of cancer compared to placebo, causing widespread public concern.

nani
Download Presentation

Background and Objective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Background and Objective • In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S) was associated with a significantly increased risk of cancer compared to placebo, causing widespread public concern. • We examined the rates of cancer adverse event reports filed with the US Food and Drug Administration (FDA) of patients on ezetimibe or E/S, and compared these to reports with other potent cholesterol-lowering drugs. Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  2. Methods • We tabulated all adverse event reports listing ‘‘cancer’’ or ‘‘malignancy’’ filed with the FDA (July 2004 to March 2008) of patients taking ezetimibe or E/S, and compared those to reports of patients taking simvastatin, atorvastatin, or rosuvastatin. • We calculated rates for such reports per million prescriptions. A secondary analysis examined cancer reports as a proportion of all reported adverse events for each medication. Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  3. Results • Prescriptions for all drugs totaled 559 million (approximately 52 and 55 million prescriptions of ezetimibe and E/S, respectively), and cancer adverse event reports totaled 2334. • There were 2.9 and 1.3 cancer-associated adverse event reports per million ezetimibe or E/S prescriptions, respectively, compared to a range of 3.1 to 5.1 per million prescriptions for the other drugs. Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  4. Results • Findings were similar when only reports listing the drug as ‘‘suspect’’ were considered. • The proportions of reports listing cancer relative to all adverse event reports were 2.0% and 1.9% for ezetimibe and E/S, respectively, compared to a range of 1.3% to 3.9% for the other drugs. Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  5. Results Table 1: Characteristics of cancer associated adverse event reports. Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  6. Results *P < 0.01 versus ezetimibe/simvastatin †P < 0.01 versus ezetimibe Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  7. Results *P < 0.01 versus ezetimibe/simvastatin †P < 0.01 versus ezetimibe Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  8. Results Table 2: Rates of cancer associated adverse event reports in patients treated with the combination ezetimibe/simvastatin and other potent cholesterol lowering drugs (rate per million prescriptions). Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

  9. Conclusions • This large-scale post-marketing analysis of reported adverse events does not support that ezetimibe or E/S increase the risk of cancer. Alsheikh-Ali and Karas JCL 3(2):138-142, 2009

More Related